
Gilead Sciences, Inc.
GILDAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 4, 2026 | Jefferies | Akash Tewari | $196.00(+17%) | $167.47 | StreetInsider |
| Nov 2, 2026 | Bernstein | Courtney Breen | $175.00(+5%) | $167.33 | StreetInsider |
| Oct 30, 2026 | UBS | Michael Yee | $195.00(+14%) | $170.95 | StreetInsider |
| Oct 30, 2026 | Needham | $175.00(+6%) | $165.61 | StreetInsider | |
| Oct 30, 2026 | BMO Capital | Evan David Seigerman | $184.00(+11%) | $165.61 | StreetInsider |
| Oct 23, 2026 | Jefferies | Akash Tewari | $185.00(+18%) | $157.19 | StreetInsider |
| Oct 12, 2026 | Raymond James | $164.00(+8%) | $151.17 | StreetInsider | |
| Oct 8, 2026 | RBC Capital | Brian Abrahams | $126.00(-13%) | $145.64 | TheFly |
| Oct 7, 2026 | Truist Financial | $158.00(+7%) | $147.53 | TheFly | |
| Sep 10, 2026 | HSBC | Morten Herholdt | $175.00(+20%) | $145.65 | TheFly |
| Aug 5, 2026 | Truist Financial | $150.00(+13%) | $132.75 | TheFly | |
| Aug 5, 2026 | RBC Capital | $123.00(-9%) | $135.25 | TheFly | |
| Jul 29, 2026 | Barclays | $145.00(+8%) | $134.32 | TheFly | |
| Jul 27, 2026 | Morgan Stanley | $165.00(+26%) | $131.23 | TheFly | |
| Jul 20, 2026 | Leerink Partners | Daina Graybosch | $127.00(-5%) | $133.21 | TheFly |
| Jul 8, 2026 | Morgan Stanley | $166.00(+22%) | $136.36 | TheFly | |
| Jul 7, 2026 | RBC Capital | Brian Abrahams | $120.00(-7%) | $129.61 | TheFly |
| Jul 6, 2026 | HSBC | Rajesh Kumar | $155.00(+18%) | $131.27 | StreetInsider |
| Jun 1, 2026 | RBC Capital | Brian Abrahams | $122.00(-9%) | $134.43 | StreetInsider |
| May 20, 2026 | Maxim Group | Michael Okunewitch | $165.00(+26%) | $130.55 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Needham | maintain | Buy | Oct 30, 2026 |
| Cantor Fitzgerald | maintain | Overweight | Oct 30, 2026 |
| JP Morgan | maintain | Overweight | Oct 30, 2026 |
| Citigroup | maintain | Buy | Oct 30, 2026 |
| Scotiabank | maintain | Sector Outperform | Oct 30, 2026 |
| TD Cowen | maintain | Buy | Oct 30, 2026 |
| Morgan Stanley | maintain | Overweight | Oct 30, 2026 |
| Wells Fargo | maintain | Overweight | Oct 30, 2026 |
| Truist Securities | maintain | Buy | Oct 30, 2026 |
| RBC Capital | maintain | Sector Perform | Oct 30, 2026 |
| UBS | maintain | Buy | Oct 30, 2026 |
| B of A Securities | maintain | Buy | Oct 20, 2026 |
| RBC Capital | maintain | Sector Perform | Oct 8, 2026 |
| Cantor Fitzgerald | maintain | Overweight | Oct 8, 2026 |
| Morgan Stanley | maintain | Overweight | Oct 7, 2026 |
| JP Morgan | maintain | Overweight | Oct 7, 2026 |
| Truist Securities | maintain | Buy | Oct 7, 2026 |
| HSBC | maintain | Buy | Sep 10, 2026 |
| RBC Capital | maintain | Sector Perform | Aug 5, 2026 |
| Needham | maintain | Buy | Aug 5, 2026 |
| Cantor Fitzgerald | maintain | Overweight | Aug 5, 2026 |
| Barclays | maintain | Equal Weight | Jul 29, 2026 |
| Morgan Stanley | maintain | Overweight | Jul 27, 2026 |
| Leerink Partners | downgrade | Outperform →Market Perform | Jul 21, 2026 |
| Morgan Stanley | maintain | Overweight | Jul 8, 2026 |
Earnings History
Next report: Feb 9, 2027 · EPS est. $1.39| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 29, 2026 | $2.55 | $2.19 | $8.30B | $7.81B |
| Aug 4, 2026 | $-6.75 | $-7.25 | $7.80B | $7.40B |
| May 7, 2026 | $2.03 | $1.91 | $6.96B | $6.91B |
| Feb 10, 2026 | $1.86 | $1.81 | $7.92B | $7.69B |
| Oct 30, 2025 | $2.47 | $2.13 | $7.77B | $7.45B |
| Aug 7, 2025 | $2.01 | $1.96 | $7.08B | $6.98B |
| Apr 24, 2025 | $1.81 | $1.78 | $6.67B | $6.81B |
| Feb 11, 2025 | $1.90 | $1.74 | $7.57B | $7.15B |
News
These are among the best the industry has to offer.
A red ink EPS figure usually spells trouble for retirees counting on a payout. Gilead's loss traces back to one strange quarter, and a single cash metric reveals whether the dividend checks are really at risk.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the detailed results from the Phase 3 IDEAL study, which demonstrated that the majority of participants living with PBC and treated with Livdelzi® (seladelpar) achieved the alkaline phosphatase (ALP) normalization composite endpoint defined as a composite of ALP ≤ 1.0× upper limit of normal (ULN) and a ≥ 15% decrease from baseline. ALP is a key marker of disease activity and long-term outcomes in PBC. The.
Gilead's HIV therapies generate strong free cash flow. The company is successfully branching out into oncology and anti-inflammatory therapies.
Ascent Group LLC cut its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 11.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 56,100 shares of the biopharmaceutical company's stock after selling 7,256 shares during the quarter. Ascent Group LLC's holdings
Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock investors acquired 16,499 put options on the stock. This is an increase of 107% compared to the average volume of 7,952 put options. Gilead Sciences Trading Up 4.2% Shares of Gilead Sciences stock opened at
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced 23 presentations, including 7 oral presentations, will be presented at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition (December 12–15, 2026). These latest clinical milestones demonstrate transformative progress across Gilead and Kite's pipeline and portfolio, from new data for the investigational anitocabtagene autoleucel (anito-cel) in relapsed or.
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2026), taking place from November 8-11. As a leader in HIV innovation, Gilead will share new clinical data and real-world evidence from its HIV research and development programs and provide updates on its strategic initiatives and key collaborations. Results from more than 50 studies, including la…
Bank Julius Baer and Co. Ltd Zurich increased its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 22.3% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,038,316 shares of the biopharmaceutical company's stock after buying an additional
The company is having a great year.
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:Wolfe Research Healthcare Conference on Tuesday, November 10 at 11:20 AM Eastern TimeUBS Global Biopharma Conference on Tuesday, November 17 at 10:00 AM Greenwich Mean TimeJefferies Global Healthcare Conference on Tuesday, November 17 at 2:30 PM Greenwich Mean TimeCiti's Global Healthcare Conference on Tuesday, December 1 at…
Gilead Sciences, Inc. delivered its strongest growth in a decade, with Q3 revenues up 16% ex-Veklury and robust HIV franchise performance. GILD's HIV division remains dominant, but Biktarvy faces 2028 Medicare price controls, expected to reduce revenue by $1.5bn that year. Oncology and immunology franchises lag, with mixed M&A results and limited near-term growth outside HIV despite heavy investment.
Gilead tops Q3 earnings and revenue estimates as HIV sales, Trodelvy and Livdelzi drive growth, prompting an increase in 2026 product sales guidance.
Gilead Sciences, Inc. GILD raised its 2026 sales outlook following strong third-quarter growth while providing new details on a significant Biktarvy pricing headwind expected in 2028.
Gilead Sciences faces valuation headwinds despite strong Q3 results and successful HIV, Trodelvy, and Yeztugo growth. Medicare pricing will reduce Biktarvy revenue by $1.5 billion annually starting in 2028, intensifying GILD's dependence on HIV. Q3 HIV growth was inflated by inventory build and a favorable channel mix, making it unsustainable for future quarters.
Gilead Sciences had a strong Q3. Sales of Trodelvy, a Trop-2-directed antibody-drug conjugate approved for the treatment of breast cancer, were $506 million, up 41.7% YoY and 10.7% QoQ. On October 22, Gilead agreed to acquire PepStar's oral IL-23R inhibitor program, including HCXT-2001, for $1.275 billion upfront.
Gilead Sciences, Inc. (NASDAQ:GILD) reported better-than-expected earnings for the third quarter on Thursday.
Gilead Sciences, Inc. ( GILD ) Q3 2026 Earnings Call October 29, 2026 4:30 PM EDT Company Participants Jacquie Ross - Senior Vice President of Treasury & Investor Relations Daniel O'Day - Chairman & CEO Johanna Mercier - Chief Commercial & Corporate Affairs Officer Dietmar Berger - Chief Medical Officer Andrew Dickinson - Executive VP & CFO Cindy Perettie - Executive Vice President of Kite Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Akash Tew…
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.